Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2013 Apr 15;23(8):2384-90. doi: 10.1016/j.bmcl.2013.02.028. Epub 2013 Feb 14.

Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.

Author information

1
Medicinal Chemistry, Bayer HealthCare AG, 13353 Berlin, Germany. ingo.hartung@bayer.com

Abstract

Using PD325901 as a starting point for identifying novel allosteric MEK inhibitors with high cell potency and long-lasting target inhibition in vivo, truncation of its hydroxamic ester headgroup was combined with incorporation of alkyl and aryl ethers at the neighboring ring position. Whereas alkoxy side chains did not yield sufficient levels of cell potency, specifically substituted aryloxy groups allowed for high enzymatic and cellular potencies. Sulfamide 28 was identified as a highly potent MEK inhibitor with nanomolar cell potency against B-RAF (V600E) as well as Ras-mutated cell lines, high metabolic stability and resulting long half-lives. It was efficacious against B-RAF as well as K-Ras driven xenograft models and showed-despite being orally bioavailable and not a P-glycoprotein substrate-much lower brain/plasma exposure ratios than PD325901.

PMID:
23474388
DOI:
10.1016/j.bmcl.2013.02.028
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center